Press release
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including topline data from the Phase 1 clinical trial of KER-050, at the 25th Annual Congress of the European Hematology Association (“EHA”), to be held as a virtual event from June 11-14, 2020.\n “We are pleased to be given the opportunity to present at this year’s virtual Congress,” said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. “We look forward to sharing these exciting data from our two lead programs with the EHA community.” Details of the presentations are as follows: “Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets” Abstract Number: EP806Date and Time: Virtual poster presentation available June 11-14, 2020 “KER-050, A Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys” Abstract Number: EP782Date and Time: Virtual poster presentation available June 11-14, 2020 “KER-050, a Novel Inhibitor of TGFΒ Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis Abstract Number: EP786Date and Time: Virtual poster presentation available June 11-14, 2020 “Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA)” Abstract Number: S308Date and Time: Virtual oral presentation available June 11-14, 2020 About KER-050 Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the Transforming Growth Factor-Beta, or TGF-ß, receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibros...